Resistance to antibiotics: are we in the post-antibiotic era?
暂无分享,去创建一个
[1] B. Robinson-Dunn,et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. , 1999, The New England journal of medicine.
[2] M. Kollef,et al. Antibiotic Resistance in the Intensive Care Unit , 2001, Annals of Internal Medicine.
[3] R. Wenzel,et al. The antibiotic pipeline--challenges, costs, and values. , 2004, The New England journal of medicine.
[4] S. Deresinski. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] R. Polk,et al. Antimicrobial use and bacterial resistance. , 2000, Current opinion in microbiology.
[6] Livermore,et al. Antimicrobials: better use, better drugs, or both? , 2000, Current Opinion in Microbiology.
[7] P. Weller,et al. Antiparasitic drugs. , 1996, The New England journal of medicine.
[8] G. Jacoby,et al. The new beta-lactamases. , 2005, The New England journal of medicine.
[9] C. J. Thomson,et al. Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges. , 2004, Current opinion in microbiology.
[10] P. Fey,et al. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. , 2003, Drugs.
[11] J. Williams,et al. Antibiotic resistance in Haemophilus influenzae: epidemiology, mechanisms, and therapeutic possibilities. , 1986, Reviews of infectious diseases.
[12] A. Pantosti,et al. Antibiotic use: the crystal ball for predicting antibiotic resistance. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] J. Picazo. Management of the febrile neutropenic patient: a consensus conference. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] E. Wald,et al. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. , 2002, The New England journal of medicine.
[15] S. Levy,et al. Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.
[16] B. Oppenheim. The changing pattern of infection in neutropenic patients. , 1998, The Journal of antimicrobial chemotherapy.
[17] G. Jacoby,et al. Mechanisms of disease: The new β-lactamases , 2005 .
[18] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[19] R. Hancock,et al. Are we approaching the end of the antibiotic era , 1998 .
[20] L. Saravolatz,et al. Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak. , 1982, Annals of internal medicine.
[21] M. Cetron,et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. , 1995, The New England journal of medicine.
[22] D G White,et al. The isolation of antibiotic-resistant salmonella from retail ground meats. , 2001, The New England journal of medicine.
[23] S. Projan,et al. Why is big Pharma getting out of antibacterial drug discovery? , 2003, Current opinion in microbiology.
[24] M. Jacobs. Streptococcus pneumoniae: epidemiology and patterns of resistance. , 2004, The American journal of medicine.
[25] R. Wunderink,et al. Increasing threat of Gram-negative bacteria , 2001, Critical care medicine.
[26] T. Perl,et al. Vancomycin-resistant enterococci: a road map on how to prevent the emergence and transmission of antimicrobial resistance. , 2003, Chest.
[27] H. Jaffe,et al. Infections due to penicillinase-producing Neisseria gonorrhoeae in the United States: 1976-1980. , 1981, The Journal of infectious diseases.
[28] J. Patterson,et al. Antibiotic utilization: is there an effect on antimicrobial resistance? , 2001, Chest.
[29] F. Lowy. Staphylococcus aureus infections. , 2009, The New England journal of medicine.
[30] D. Malone,et al. Excessive antibiotic use for acute respiratory infections in the United States. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] M. Roberts,et al. Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution. , 1996, FEMS microbiology reviews.
[32] P. Huovinen. Macrolide-resistant group a streptococcus--now in the United States. , 2002, The New England journal of medicine.
[33] P. Fey,et al. Ceftriaxone-resistant salmonella infection acquired by a child from cattle. , 2000, The New England journal of medicine.
[34] D. Guillemot,et al. Antibiotic use in humans and bacterial resistance. , 1999, Current opinion in microbiology.
[35] J. Versalovic,et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] S. Levy. The antibiotic paradox : how the misuse of antibiotics destroys their curative powers , 2002 .
[37] R. Leclercq,et al. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[38] Christopher Dye,et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. , 2001, The New England journal of medicine.
[39] H. Morton,et al. Staphylococcus aureus , 1948, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[40] M. Cetron,et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. , 2000, The New England journal of medicine.
[41] J. Jorgensen,et al. Update on mechanisms and prevalence of antimicrobial resistance in Haemophilus influenzae. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[42] D. Melé. 21 ST -CENTURY , 2007 .
[43] G. Boivin,et al. Human Cytomegalovirus Resistance to Antiviral Drugs , 2005, Antimicrobial Agents and Chemotherapy.
[44] J. Butler,et al. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. , 1998, The New England journal of medicine.
[45] S. Hori,et al. Mechanisms of antimicrobial resistance , 1989 .
[46] G. Jacoby,et al. The New b -Lactamases , 2005 .
[47] A. Tomasz,et al. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. , 1999, The New England journal of medicine.
[48] J. Besser,et al. Quinolone-ResistantCampylobacter jejuniInfections in Minnesota, 1992–1998 , 1999 .
[49] H L Rieder,et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. , 1998, The New England journal of medicine.
[50] I Lind,et al. Epidemiology of antibiotic resistant Neisseria gonorrhoeae in industrialized and developing countries. , 1990, Scandinavian journal of infectious diseases. Supplementum.
[51] D. Monnet,et al. Transient intestinal carriage after ingestion of antibiotic-resistant Enterococcus faecium from chicken and pork. , 2001, The New England journal of medicine.
[52] C. Rammelkamp,et al. Resistance of Staphylococcus aureus to the Action of Penicillin.∗ , 1942 .
[53] H. Wegener. The consequences for food safety of the use of fluoroquinolones in food animals. , 1999, The New England journal of medicine.
[54] S. Polly. The Antibiotic Paradox: How the Misuse of Antibiotics Destroys Their Curative Powers , 2002 .
[55] Donald Morrison,et al. Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillin-resistant clone , 2005, The Lancet.
[56] F. Lowy. Antimicrobial resistance: the example of Staphylococcus aureus. , 2003, The Journal of clinical investigation.
[57] J. Powers,et al. Trends in antimicrobial drug development: implications for the future. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[58] D. Hooper. Efflux pumps and nosocomial antibiotic resistance: a primer for hospital epidemiologists. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[59] L Lasagna,et al. Cost of innovation in the pharmaceutical industry. , 1991, Journal of health economics.
[60] T. File. Streptococcus pneumoniae and community-acquired pneumonia: A cause for concern , 2004, The American Journal of Medicine Supplements.
[61] D. Kontoyiannis,et al. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century , 2005, Cancer.
[62] F. Waldvogel. New resistance in Staphylococcus aureus. , 1999, The New England journal of medicine.
[63] A. Tomasz. The pneumococcus at the gates. , 1995, The New England journal of medicine.
[64] A. Tomasz,et al. The challenge of antibiotic resistant bacterial pathogens: the medical need, the market and prospects for new antimicrobial agents. , 2004, Current opinion in microbiology.
[65] L. Rice,et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. , 2000, The New England journal of medicine.
[66] T. Foster. The Staphylococcus aureus "superbug". , 2004, The Journal of clinical investigation.
[67] G. Amsden. Pneumococcal resistance in perspective: how well are we combating it? , 2004, The Pediatric infectious disease journal.
[68] K. Seme,et al. The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens. , 2001, The Journal of antimicrobial chemotherapy.
[69] D. Shlaes,et al. The United States Food and Drug Administration and the end of antibiotics. , 1935, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[70] P Huovinen,et al. Outpatient use of erythromycin: link to increased erythromycin resistance in group A streptococci. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[71] O. Vanderkooi,et al. Predicting antimicrobial resistance in invasive pneumococcal infections. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[72] D. Gilbert,et al. Is there hope for the prevention of future antimicrobial shortages? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[73] M. Ghannoum,et al. Mechanisms of fungal resistance: an overview. , 2002, Drugs.
[74] F. Saulnier,et al. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit* , 2005, Critical care medicine.